IGM Biosciences to Present at Three Upcoming Investor Conferences
IGM Biosciences (Nasdaq: IGMS), a clinical-stage biotechnology company focused on engineered IgM antibodies, has announced its participation in three major investor conferences in November 2024. The company will present at the Guggenheim Healthcare Innovation Conference in Boston (Nov. 11), the Stifel Healthcare Conference in New York (Nov. 19), and the Jefferies London Healthcare Conference in London (Nov. 21).
Live webcasts of all presentations will be accessible through the company's investor relations website, with recordings available for 90 days post-presentation.
IGM Biosciences (Nasdaq: IGMS), un'azienda biotecnologica in fase clinica specializzata negli anticorpi IgM ingegnerizzati, ha annunciato la sua partecipazione a tre importanti conferenze per investitori a novembre 2024. L'azienda presenterà alla Guggenheim Healthcare Innovation Conference a Boston (11 novembre), alla Stifel Healthcare Conference a New York (19 novembre) e alla Jefferies London Healthcare Conference a Londra (21 novembre).
Le trasmissioni in diretta di tutte le presentazioni saranno accessibili attraverso il sito web delle relazioni con gli investitori dell'azienda, con registrazioni disponibili per 90 giorni dopo la presentazione.
IGM Biosciences (Nasdaq: IGMS), una empresa de biotecnología en etapa clínica centrada en anticuerpos IgM diseñados, ha anunciado su participación en tres importantes conferencias de inversores en noviembre de 2024. La empresa presentará en la Guggenheim Healthcare Innovation Conference en Boston (11 de noviembre), en la Stifel Healthcare Conference en Nueva York (19 de noviembre) y en la Jefferies London Healthcare Conference en Londres (21 de noviembre).
Las transmisiones en vivo de todas las presentaciones serán accesibles a través del sitio web de relaciones con inversores de la empresa, con grabaciones disponibles durante 90 días después de la presentación.
IGM Biosciences (Nasdaq: IGMS)는 엔지니어링된 IgM 항체에 집중하는 임상 단계의 생명공학 회사로, 2024년 11월에 열리는 세 개의 주요 투자자 회의에 참가한다고 발표했습니다. 이 회사는 보스턴에서 열리는 Guggenheim Healthcare Innovation Conference (11월 11일), 뉴욕에서 열리는 Stifel Healthcare Conference (11월 19일), 런던에서 열리는 Jefferies London Healthcare Conference (11월 21일)에서 발표할 예정입니다.
모든 발표의 실시간 웹캐스트는 회사의 투자자 관계 웹사이트를 통해 접속할 수 있으며, 발표 후 90일 동안 녹화본이 제공됩니다.
IGM Biosciences (Nasdaq: IGMS), une entreprise de biotechnologie en phase clinique spécialisée dans les anticorps IgM ingénierie, a annoncé sa participation à trois grandes conférences pour investisseurs en novembre 2024. L'entreprise présentera à la Guggenheim Healthcare Innovation Conference à Boston (11 novembre), à la Stifel Healthcare Conference à New York (19 novembre) et à la Jefferies London Healthcare Conference à Londres (21 novembre).
Des webdiffusions en direct de toutes les présentations seront accessibles via le site web des relations investisseurs de l'entreprise, avec des enregistrements disponibles pendant 90 jours après la présentation.
IGM Biosciences (Nasdaq: IGMS), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf entwickelte IgM-Antikörper konzentriert, hat seine Teilnahme an drei bedeutenden Investorenkonferenzen im November 2024 angekündigt. Das Unternehmen wird auf der Guggenheim Healthcare Innovation Conference in Boston (11. November), der Stifel Healthcare Conference in New York (19. November) und der Jefferies London Healthcare Conference in London (21. November) präsentieren.
Die Live-Webcasts aller Präsentationen sind über die Investor Relations-Website des Unternehmens zugänglich, und Aufzeichnungen sind 90 Tage nach der Präsentation verfügbar.
- None.
- None.
MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will present at three upcoming investor conferences:
- Guggenheim Healthcare Innovation Conference on Monday, November 11 at 11:30 a.m. EST in Boston
- Stifel Healthcare Conference on Tuesday, November 19 at 12:40 p.m. EST in New York
- Jefferies London Healthcare Conference on Thursday, November 21 at 8:00 a.m. GMT/ 3:00 a.m. EST in London
A live webcast of the events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcasts will be archived on the Company’s website for 90 days following the presentations.
About IGM Biosciences, Inc.
IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with autoimmune and inflammatory diseases. IGM’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only 2 binding sites. IGM also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against immunology and inflammation targets. For more information, please visit www.igmbio.com.
Contact:
Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com
FAQ
What investor conferences will IGM Biosciences (IGMS) attend in November 2024?
Where can I watch IGM Biosciences (IGMS) investor conference presentations?
What time is IGM Biosciences' (IGMS) presentation at the Jefferies London Healthcare Conference?
